Nephrotic Syndrome Associated with Lung Cancer: A Rare Case of Malignancy Associated with AA Amyloidosis

Nonhematologic malignancies are rarely reported to be associated with AA amyloidosis. Although the association between renal cell carcinoma and systemic AA amyloidosis has been established, the evidence linking pulmonary cancer to AA amyloidosis is scarce. Here, a case of biopsy-proven renal AA amyloidosis complicated with nephrotic syndrome associated with lung carcinoma is reported.

Download Full-text

Renal Cell Carcinoma Presenting as Nephrotic Syndrome

Nephron ◽

10.1159/000188434 ◽

1995 ◽

Vol 69 (2) ◽

pp. 166-169 ◽

Cited By ~ 5

Author(s):

G. Woodrow ◽

A. Innes ◽

I.D. Ansell ◽

R.P. Burden

Keyword(s):

Renal Cell Carcinoma ◽

Nephrotic Syndrome ◽

Cell Carcinoma ◽

Renal Cell

Download Full-text

Metastatic clear cell renal cell carcinoma presenting as breast lump: A rare case report

Diagnostic Cytopathology ◽

10.1002/dc.24710 ◽

2021 ◽

Author(s):

Vikrant Verma ◽

Amrin Israrahmed ◽

Ram N. Rao

Keyword(s):

Renal Cell Carcinoma ◽

Case Report ◽

Cell Carcinoma ◽

Renal Cell ◽

Rare Case ◽

Clear Cell ◽

Breast Lump ◽

Cell Renal Cell Carcinoma ◽

Rare Case Report

Download Full-text

Predictors of immunotherapy-induced immune-related adverse events

Current Oncology ◽

10.3747/co.25.4047 ◽

2018 ◽

Vol 25 (5) ◽

Cited By ~ 14

Author(s):

A. Kartolo ◽

J. Sattar ◽

V. Sahai ◽

T. Baetz ◽

J. M. Lakoff

Keyword(s):

Lung Cancer ◽

Renal Cell Carcinoma ◽

Adverse Events ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Cell Lung Cancer ◽

Renal Cell ◽

Small Cell ◽

Small Cell Lung ◽

Goodness Of Fit Test

Purpose We aimed to elucidate predictive factors for the development of immune-related adverse events (iraes) in patients receiving immunotherapies for the management of advanced solid cancers.Methods This retrospective study involved all patients with histologically confirmed metastatic or inoperable melanoma, non-small-cell lung cancer, or renal cell carcinoma receiving immunotherapy at the Cancer Centre of Southeastern Ontario. The type and severity of iraes, as well as potential protective and exacerbating factors, were collected from patient charts.ResultsThe study included 78 patients receiving ipilimumab (32%), nivolumab (33%), or pembrolizumab (35%). Melanoma, non-small-cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the cancers in the study population. In 41 patients (53%) iraes developed, with multiple iraes developing in 12 patients (15%). In most patients (70%), the iraes were of severity grade 1 or 2. Female sex [adjusted odds ratio (oradj): 0.094; 95% confidence interval (ci): 0.021 to 0.415; p = 0.002] and corticosteroid use before immunotherapy (oradj: 0.143; 95% ci: 0.036 to 0.562; p = 0.005) were found to be associated with a protective effect against iraes. In contrast, a history of autoimmune disease (oradj: 9.55; 95% ci: 1.34 to 68.22; p = 0.025), use of ctla-4 inhibitors (oradj: 6.25; 95% ci: 1.61 to 24.25; p = 0.008), and poor kidney function of grade 3 or greater (oradj: 10.66; 95% ci: 2.41 to 47.12; p = 0.025) were associated with a higher risk of developing iraes. A Hosmer–Lemeshow goodness-of-fit test demonstrated that the logistic regression model was effective at predicting the development of iraes (chi-square: 1.596; df = 7; p = 0.979).Conclusions Our study highlights several factors that affect the development of iraes in patients receiving immunotherapy. Although future studies are needed to validate the resulting model, findings from the study can help to guide risk stratification, monitoring, and management of iraes in patients given immunotherapy for advanced cancer.

Download Full-text

Adrenal metastases: clinical manifestations and surgical outcomes

Cancer Urology ◽

10.17650/1726-9776-2018-14-2-79-87 ◽

2018 ◽

Vol 14 (2) ◽

pp. 79-87 ◽

Cited By ~ 1

Author(s):

V. R. Latypov ◽

O. S. Popov ◽

V. N. Latypova ◽

M. Yu. Grishchenko

Keyword(s):

Lung Cancer ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Tumor Size ◽

Renal Cell ◽

Clinical Manifestations ◽

Adrenal Metastasis ◽

Adrenal Metastases ◽

The Mean ◽

Mean Time

Background. The adrenal glands are one of the most common sites of metastases in malignant disease, particularly lung cancer. The frequency of adrenal metastasis in patients with breast cancer and lung cancer reaches 39 and 35 % respectively.Materials and methods. A total of 156 patients with adrenal tumors underwent surgical treatment in the Siberian State Medical University between December 1998 and July 2017. The study included 16 (10.2 %) patients (9 males and 7 females) with adrenal metastases. The mean age of study participants was 57.6 years (range: 44–73 years).Results. By the moment of surgery, the mean metastatic adrenal tumor size was 4.9 ± 3.0 cm (range: 1.0–10.2 cm). Thirteen out of 16 patients had adrenal metastases from renal cell carcinoma, one patient – from colon cancer, one patient – from lung cancer, and one patient – from breast cancer. Nine patients had left-sided adrenal metastases, whereas six patients had right-sided adrenal metastases. Synchronous adrenal metastasis was detected in two cases: one patient had adrenal metastasis at the side of the renal tumor; the other one had bilateral renal cell carcinoma with both adrenal glands affected.We identified three main variants of the disease course according to prevailing clinical manifestations of adrenal metastasis: no manifestations, pain syndrome, and arterial hypertension.Seven participants had no clinical manifestations; of them, 6 patients had renal cell carcinoma, whereas 1 patient had breast cancer. The mean time between surgical removal of the primary tumor and detection of adrenal metastases was 24.1 months; the mean tumor size was 4.5 cm.Pain syndrome was observed in 5 patients. In three of them, adrenal metastases derived from renal cell carcinoma, in one patient – from lung cancer, and in one patient – from colon cancer. The mean time between removal of the primary tumor and detection of adrenal metastases was 19.8 months; the mean tumor size was 5.4 cm.Arterial hypertension was diagnosed in four patients. The mean time between removal of the primary tumor and identification of adrenal metastases was 27.3 months; the mean tumor size was 4.1 cm. The five-year overall survival rate in operated patient was 47.8 %.Conclusion. Regular examinations of patients after surgical treatment of malignant tumors are needed to detect adrenal metastases; surgery can extend the patient’s life. can extend the patient’s life.

Download Full-text